TARO PHARMACEUTICAL INDS LTD's ticker is TARO and the CUSIP is M8737E108. A total of 96 filers reported holding TARO PHARMACEUTICAL INDS LTD in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,673 | -99.1% | 70,870 | +1537.5% | 0.00% | – |
| Q2 2021 | $311,000 | -76.0% | 4,328 | -81.7% | 0.00% | -100.0% |
| Q3 2020 | $1,295,000 | -51.5% | 23,607 | -41.3% | 0.00% | -60.0% |
| Q2 2020 | $2,672,000 | +990.6% | 40,190 | +904.8% | 0.01% | +400.0% |
| Q1 2020 | $245,000 | -94.9% | 4,000 | -92.7% | 0.00% | -90.9% |
| Q4 2019 | $4,793,000 | -53.9% | 54,506 | -60.5% | 0.01% | -54.2% |
| Q3 2019 | $10,404,000 | -19.8% | 137,899 | -9.2% | 0.02% | -17.2% |
| Q2 2019 | $12,974,000 | -28.1% | 151,879 | -9.0% | 0.03% | -32.6% |
| Q1 2019 | $18,045,000 | +11.5% | 166,942 | -12.7% | 0.04% | +2.4% |
| Q4 2018 | $16,184,000 | -20.3% | 191,208 | -7.4% | 0.04% | -8.7% |
| Q3 2018 | $20,304,000 | -16.9% | 206,547 | -2.2% | 0.05% | -23.3% |
| Q2 2018 | $24,439,000 | +848.7% | 211,247 | +709.7% | 0.06% | +900.0% |
| Q1 2018 | $2,576,000 | -76.8% | 26,091 | -75.4% | 0.01% | -77.8% |
| Q4 2017 | $11,093,000 | – | 105,941 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ISZO CAPITAL MANAGEMENT LP | 582,409 | $90,011,000 | 60.33% |
| GUARDIAN POINT CAPITAL, LP | 70,000 | $10,819,000 | 10.19% |
| Think Investments LP | 186,373 | $28,804,000 | 8.16% |
| Greywolf Capital Management LP | 277,936 | $42,955,000 | 7.45% |
| Valentine Capital Asset Management, Inc. | 28,431 | $4,394,000 | 4.91% |
| FORT, L.P. | 63,675 | $9,841,000 | 4.69% |
| MATTHEWS INTERNATIONAL CAPITAL MANAGEMENT LLC | 527,266 | $81,489,000 | 3.63% |
| RPG Investment Advisory, LLC | 60,910 | $9,413,000 | 3.52% |
| Kerrisdale Advisers, LLC | 81,996 | $12,672,000 | 3.24% |
| Strategic Global Advisors, LLC | 48,154 | $7,442,000 | 3.17% |